Media coverage about Fulgent Genetic (NASDAQ:FLGT) has trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fulgent Genetic earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.5937902186772 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern’s scoring:
- Fulgent Genetic (FLGT) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Fulgent Genetic (FLGT) CEO Buys $39,974.40 in Stock (americanbankingnews.com)
- Analyzing Digirad Corporation (DRAD) and Fulgent Genetic (FLGT) (americanbankingnews.com)
- Edited Transcript of FLGT earnings conference call or presentation 6-Nov-17 10:00pm GMT (finance.yahoo.com)
- Fulgent Genetic (FLGT) Price Target Cut to $7.50 by Analysts at Credit Suisse Group (americanbankingnews.com)
Fulgent Genetic (NASDAQ:FLGT) traded down $0.06 on Tuesday, reaching $3.26. The company had a trading volume of 74,400 shares, compared to its average volume of 44,234. Fulgent Genetic has a 12-month low of $2.72 and a 12-month high of $13.90. The firm has a market capitalization of $58.90 and a PE ratio of 166.00.
Several brokerages have recently weighed in on FLGT. Piper Jaffray Companies restated an “overweight” rating and set a $7.00 target price (down from $10.00) on shares of Fulgent Genetic in a report on Wednesday, August 9th. Zacks Investment Research cut Fulgent Genetic from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine upgraded Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Raymond James Financial, Inc. cut Fulgent Genetic from an “outperform” rating to a “mkt perform” rating in a report on Tuesday, November 7th. Finally, Credit Suisse Group AG decreased their price objective on Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $7.25.
In other Fulgent Genetic news, CEO Ming Hsieh acquired 11,520 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were purchased at an average cost of $3.47 per share, for a total transaction of $39,974.40. Following the completion of the acquisition, the chief executive officer now owns 6,506,464 shares of the company’s stock, valued at approximately $22,577,430.08. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 58.80% of the company’s stock.
Fulgent Genetic Company Profile
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with MarketBeat.com's FREE daily email newsletter.